Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Dialysis

 

Diaverum IPO pushed to 2021 as lockdowns hit growth

The IPO of international dialysis provider Diaverum by owner Bridgepoint is likely to have been pushed back to 2021, we are told. While dialysis volumes have been largely unaffected by the pandemic, lockdowns and travel restrictions may have hit its ability to reach full-year growth targets.
August 20, 2020

Adding value post-COVID – where are the easy wins?

How do you add value to a business in a post COVID world - and are there any easy wins for new acquisitions? On Wednesday last week, an online audience heard HBI365's lively Q&A panel with with Ameos CEO Dr Axel Paeger, McKinsey partner Sebastian Sieler, and L Catterton managing partner Chinta Bhagat.
July 23, 2020

Pandemic could accelerate push to home dialysis

COVID-19 could accelerate the push towards home haemodialysis and increased operator costs are unlikely to be reflected in revised tariffs, Fresenius Medical Care's global head of M&A Dr Wolfgang Hofmann tells HBI. 
May 28, 2020

Dialysis players beat COVID-19, mostly

Global dialysis operators' volumes have been largely maintained during the COVID-19 pandemic. But the long-term impact of the crisis is not so clear. 
May 7, 2020

Exclusive prediction: Pandemic reaching turning point in Europe?

An exclusive analysis by Chinese insurance giant Ping An suggests COVID-19 cases could reach a turning point in the next few days, hitting the peak of new confirmed cases by later this week / early April,  with that figure set to fall thereafter.
March 30, 2020

COVID-19: Care sector confronts crisis, hospitals hit hard

In the second of our two-part deep dive into how COVID-19 is hitting healthcare markets across EMEA, we ask how hospitals are coping with spiralling staff sickness and a flood of patients, and whether the care and dialysis sectors can stay afloat given the risk the virus poses to their most vulnerable patients.
March 12, 2020

Mexican clinic boosts low-income patients by monetising quality

With the help of a results-based financing mechanism, Mexico's largest specialised diabetes provider Clínicas del Azúcar has doubled its number of patients from the poorest segments of society and tells HBI it can now double the locations for potential clinics. We speak to its CEO and the co-creator of 'social impact incentives' about how to monetise extra value in impact investing.
February 26, 2020
Older posts
Newer posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us